Who
Tolga Tanguler
Director
Company insider
Files Form 4 as: Director, Lexeo Therapeutics; EVP, Chief Commercial Officer, Alnylam Pharmaceuticals.
In numbers
- Trades disclosed
- 210
- Buys
- 0
- Sells
- 19
- Bought
- $0
- Sold
- $11.4M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 1 Feb 2022
- Last trade
- 25 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 29 Jun 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $34K106 at $319.03 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $33K102 at $320.01 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $69K215 at $320.81 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $93K289 at $321.82 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $113K350 at $323.01 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $248K767 at $323.84 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $88K272 at $324.88 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $68K208 at $325.67 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $34K106 at $319.03 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $33K102 at $320.01 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $69K215 at $320.81 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $93K289 at $321.82 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $113K350 at $323.01 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $248K767 at $323.84 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $88K272 at $324.88 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $68K208 at $325.67 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —4,769 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $31K94 at $331.93 | filing |
News
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Reduction from Wells Fargo & CompanyALNY · tickerreport.com · 17 Oct 2026Oncocyte (NASDAQ:IMDX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) Critical SurveyALNY · tickerreport.com · 14 Oct 2026Head-To-Head Review: Novavax (NASDAQ:NVAX) & Alnylam Pharmaceuticals (NASDAQ:ALNY)ALNY · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Tolga Tanguler; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.